AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06068166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GDMT
Description: All the patients received maximally tolerated guideline-directed medical therapy (GDMT) alone.
Study NCT02699801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol for post-sternal closure sedation
Study NCT02699801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine for post-sternal closure sedation
Study NCT01054430 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: avanafil
Description: 200 mg avanafil tablets QD
Study NCT02606292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photoacoustic endoscopy
Study NCT02606292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (standard of care)
Study NCT02606292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery (standard of care)
Study NCT03767114 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: RT-PCR for ERAP1 detection
Description: Reverse transcriptase -Polymerase Chain Reaction for ERAP1 detection
Study NCT02388555 — intervention group
Intervention type: PROCEDURE
Intervention: Posterior osteotomy correction
Description: The DLS patients underwent osteotomy including pedicle subtraction osteotomy (PSO) or Smith-Petersen osteotomy (SPO)
Study NCT03719677 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit development intervention
Description: Lifestyle behavior change intervention targeting physical activity and dietary habit development as well as improving physical and social functioning
Study NCT03789799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TIAB: microcrystalline titanium dioxide with covalently linked monovalent silver ions
Description: TIAGIN vaginal capsule, composition: TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, Aloe Barbadensis Extract
Study NCT03789799 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaginal capsule, composition: Sodium Hyaluronate, Aloe Barbadensis Extract
Study NCT03074851 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low sodium salt
Description: To give free low sodium salt intervention for 2 months
Study NCT03074851 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: informational intervention
Description: to give reporter informational intervention.
Study NCT00017004 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo radiation
Study NCT04112316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liothyronine
Description: Liothyronine (L-triiodothyronine or LT3) in the 5 mcg tablet dose formulation. Minimum LT3 dose was 2.5 mcg three times daily and the maximum LT3 dose was 12.5 mcg three times daily.
Study NCT04112316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liothyronine
Description: Liothyronine (L-triiodothyronine or LT3) in the 5 mcg tablet dose formulation. Minimum LT3 dose was 2.5 mcg three times daily and the maximum LT3 dose was 12.5 mcg three times daily.
Study NCT00017004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT04112316 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A placebo tablet matching in appearance to LT3 tablets. Minimum placebo tablet dose was 1/2 tablet three times daily and the maximum placebo dose was 2 1/2 tablets three times daily.
Study NCT04112316 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo tablet matching in appearance to LT3 tablets. Minimum placebo tablet dose was 1/2 tablet three times daily and the maximum placebo dose was 2 1/2 tablets three times daily.
Study NCT04640857 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silk'n Toothwave
Description: patients will receive a non-surgical treatment which will include oral hygiene instructions, calculus removal with ultrasonic and manual instruments. At the end of the meeting they will be provided with a toothbrush which is based on a radiofrequency technology.
Study NCT04640857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silk'n Toothwave
Description: patients will receive a non-surgical treatment which will include oral hygiene instructions, calculus removal with ultrasonic and manual instruments. At the end of the meeting they will be provided with a toothbrush which is based on a radiofrequency technology.
Study NCT00017004 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Description: Undergo radiation
Study NCT00017004 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epoetin Alfa
Description: Given SC
Study NCT01107626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01107626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT04385095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo via inhalation
Study NCT05815849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olive oil
Description: 0.5 cc/30 ml of olive oil (a brand easily available in the markets) was added to the milk at each feeding of the infants in the intervention group
Study NCT01107626 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT04414137 — intervention group
Intervention type: OTHER
Intervention: Description of eosinophilic pneumonia due to daptomycine
Description: Description of eosinophilic pneumonia in patients treated by daptomycin for an osteoarticular infection
Study NCT01107626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium Heptahydrate
Description: Given IV
Study NCT02923128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 3 ug/kg is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
Study NCT02923128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanyl
Description: Sufentanyl 3 ug/kg is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
Study NCT04516330 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: miRNA
Description: miRNA's expressed in breast cancer
Study NCT02923128 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sufentanyl
Description: Sufentanyl 3 ug/kg is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
Study NCT02923128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline is used to dilute other drugs
Study NCT02923128 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Saline is used to dilute other drugs
Study NCT04499378 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung CT
Description: Computed tomography of the thorax
Study NCT04313010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRF
Description: A sample of whole venous blood was drawn from the patient's forearm. The blood sample was transferred into a tube without anticoagulant and centrifuged immediately using a centrifuge.
Study NCT04313010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BC
Description: According to the procedures of regenerative endodontics therapy, BC was made by the way of provoking apical bleeding into root canal.
Study NCT01996423 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Study NCT01280591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)
Description: Participants received two Naproxen sodium 220 mg / DPH (Diphenhydramine hydrochloride) 25 mg tablets orally, single dose
Study NCT01996423 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02250924 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: caffeinated gum
Study NCT02250924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gum
Description: Chewing gum
Study NCT02250924 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Gum
Description: Chewing gum
Study NCT01280591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)
Description: Participants received one Naproxen sodium 220 mg / DPH 50 mg tablet and one matching placebo capsule orally, single dose
Study NCT01280591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen sodium 440 mg (BAYH6689)
Description: Participants received two Naproxen sodium 220 mg tablets orally, single dose
Study NCT01280591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPH 50 mg
Description: Participants received two DPH (Diphenhydramine hydrochloride) 25mg tablets orally, single dose
Study NCT03076736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Singing group + resource pack
Description: SPA is a community-based, 10 weekly singing group. Each SPA session comprises 30 minutes of settling in/wrap-up and departure, and 60 minutes of group singing. Sessions will be led by a community music leader, co-facilitated by a person with aphasia, and involve the group singing from a songbook. Musical accompaniment will be provided by the facilitator(s). Small percussion instruments will be available for participants, enabling involvement of those with limited singing ability. Intervention content integrates the Information-Motivation-Behavioural (IMB) skills model of health behaviour change to support individuals in developing the social skills and confidence needed to improve psychosocial outcomes. Participants will also receive the resource pack.
Study NCT03076736 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resource pack
Description: Resource pack with information on living with aphasia and local community activities.
Study NCT01121783 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactisole
Description: A pre-infusion of lactisole solution (0.25mg/ml) is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes a 1M glucose solution is administered as a bolus via intragastric tube.
Study NCT01121783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactisole
Description: A pre-infusion of lactisole solution (0.25mg/ml)is administered as a bolus (1ml/kg body weight) via intragastric tube. After 15 minutes tap water will be administered as a bolus via the intragastric tube.
Study NCT01121783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactisole
Description: A pre-infusion of tap water(is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes a 1M glucose solution is administered as a bolus via intragastric tube.
Study NCT01121783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactisole
Description: A pre-infusion of tap water is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes tap water is administered as a bolus via intragastric tube.
Study NCT02380430 — intervention group
Intervention type: OTHER
Intervention: ambulatory surgery description
Description: Medical questionnaire. Nausea and vomiting, pain, thromboprophylaxis description
Study NCT02620332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MultiPepT1De injection
Description: A mix of peptides
Study NCT02620332 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Water for injection
Study NCT02250924 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: wear silicone bracelet
Description: Subjects will put on bracelet to correspond with times for chewing gum
Study NCT02390557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey
Description: PDQS survey reports only
Study NCT00523289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Dosage: 150mg at once for anesthesia induction
Study NCT00523289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Single dose of ropivacaine, 150mg
Study NCT02390557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: YESHealth
Description: Arm 3: YESHealth and PDQS survey reports to providers
Study NCT03263793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choral (group) singing therapy sessions
Description: Choral (group) singing therapy sessions will be conducted once weekly and daily home practice exercises will be assigned. All vocal exercises are based on principles that have been successful in other intensive Parkinson Disease vocal exercise programs.
Study NCT00768183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KADIAN Capsule + alcohol (under fasting conditions)
Description: Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
Study NCT00768183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KADIAN Capsule + water (under fasting conditions)
Description: Capsules 100mg + 240 mL in 4 shots of 60 mL
Study NCT00768183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine sulfate IR oral solution + water
Description: Morphine sulfate IR oral solution + water (under fasting conditions)
Study NCT00768183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KADIAN Capsule + alcohol (under fed conditions)
Description: Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
Study NCT01540266 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Information structuring
Description: Students were independently shown one of two videos in which the same physician conveyed the identical 28 items of information to an older patient (played by an actor) in either structured or non-structured form
Study NCT02467491 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Jintronix
Description: The participants will perform light exercises using the Jintronix software. Jintronix is an easy-to-use virtual physical activity platform designed for physical and occupational therapy. It combines common exercise movements, virtual games and motion sensing cameras to offer a fun and effective tool for physical activity.
Study NCT01711918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone
Description: oral tablet; dose is 10mg per tablet given up to 3 times daily.
Study NCT01540266 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no information structuring
Description: Students were independently shown one of two videos in which the same physician conveyed the identical 28 items of information to an older patient (played by an actor) in either structured or non-structured form
Study NCT01227642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An ultrasound-based technique to identify prostate cancer
Description: The technique uses current ultrasound equipment already in use for prostate brachytherapy guidance.By extracting and processing the radiofrequency signal obtained from the ultrasound transducer in ways not done to create the standard B-mode ultrasound image, areas of cancer can be identified and displayed overlying the standard B-mode ultrasound image. Comparing the results with this technique to the results of prostate biopsies demonstrates a high degree of accuracy with the area under the receiver-operator characteristic curve of 0.87, a result superior to any other imaging methods.
Study NCT01227642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pre-implant transrectal ultrasound images and planning
Description: an ultrasound-based technique to identify cancer-containing areas within the prostate.
Study NCT01227642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound-based cancer-specific images
Description: ultrasound-based cancer-specific images of the prostate prior to the brachytherapy and use them to direct the dosimetry planning
Study NCT00761631 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13 valent pneumococcal conjugate vaccine
Description: Intramuscular injection of 0.5mL at visit 1 and visit 2 for group 1 and and visit 1 for groups 2, 3, and 4.
Study NCT02935842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific SL-therapy
Description: Provided by a professional speech-language therapist (SLT) on a one-to-one basis. In approx. 45 Minutes sessions, 3 times per week for 4 weeks in total.
Study NCT02935842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specific SL-therapy
Description: Provided by a professional speech-language therapist (SLT) on a one-to-one basis. In approx. 45 Minutes sessions, 3 times per week for 4 weeks in total.
Study NCT02935842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic Balance-Movement Training (rBMT)
Description: Provided on a one-to-one basis. In approx. 30-45 Minutes sessions, 3 times per week for 4 weeks in total.
Study NCT02935842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rhythmic Balance-Movement Training (rBMT)
Description: Provided on a one-to-one basis. In approx. 30-45 Minutes sessions, 3 times per week for 4 weeks in total.
Study NCT04820517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Roy Adaptation Model Based Strengthening Program
Description: Applications included in the strengthening program sessions:~* Awareness study on social media addiction and its effects~* Awareness work on the correct and effective use of leisure time~* As a result of social media addiction, within the scope of Roy Adaptation Model, scenario sharing and problem solving process related to the problems arising in the fields of physical, group identity - self, role and interdependence~* Awareness work on recognizing and managing emotions~* Relaxation and Breathing Exercise in Emotion Management
Study NCT03820271 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SuperMELD
Description: The population of this arm will consist of patients newly enrolled in the National Liver Transplantation Waiting List for decompensated cirrhosis, whose liver function and MELD score are assessed at enrollment and then routinely reassessed at least quarterly during the waiting phase.~Patients will be followed from their listing to transplantation or discharge or death.
Study NCT05498012 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: placebo dental gel, placebo toothpaste
Description: * Placebo dental gel applied by dentist after oral hygiene; without cannabidiol.~* Placebo toothpaste; without cannabidiol. For daily use by patient.
Study NCT05498012 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cannabidiol dental gel, Cannabidiol toothpaste
Description: * Cannabidiol dental gel applied by dentist after oral hygiene; containing 1 % (w/w) cannabidiol.~* Cannabidiol toothpaste; containing 1 % (w/w) cannabidiol. For daily use by patient.
Study NCT05498012 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo toothpaste, Corsodyl dental gel
Description: * Corsodyl dental gel; containing 1 % (w/w) chlorhexidini digluconatis applied by dentist after oral hygiene.~* Placebo toothpaste; without cannabidiol. For daily use by patient.
Study NCT02888301 — intervention group
Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo 18F-clofarabine PET/CT
Study NCT02888301 — intervention group
Intervention type: RADIATION
Intervention: Fluorine F 18 Clofarabine
Description: Given IV
Study NCT02888301 — intervention group
Intervention type: PROCEDURE
Intervention: Positron Emission Tomography
Description: Undergo 18F-clofarabine PET/CT
Study NCT00289016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
Study NCT00518362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TW
Description: TW,120 mg/d
Study NCT04124068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide teeth whitening gel
Description: Hydrogen peroxide teeth whitening gel with concentrations ranging between 6% - 30%
Study NCT01513798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified paleolithic diet and exercise under observation
Description: Modified paleolithic diet and exercise 3 session/week under observation
Study NCT01513798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified paleolithic diet and general advice on exercise
Description: Modified paleolithic diet and general advice on exercise
Study NCT04018963 — intervention group
Intervention type: PROCEDURE
Intervention: Single nostril approach endoscopic transsphenoidal pituitary surgery
Description: Single nostril approach endoscopic transsphenoidal pituitary surgery
Study NCT04018963 — intervention group
Intervention type: PROCEDURE
Intervention: Bilateral nostril approach endoscopic transsphenoidal pituitary surgery
Description: Bilateral nostril approach endoscopic transsphenoidal pituitary surgery
Study NCT03173820 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Genotype guided
Description: Tacrolimus will be prescribed depend on CYP3A5 genotype. CYP3A5\*1/\*1 patients will receive tacrolimus 0.125 mg/kg/day. CYP3A5\*1/\*3 patients will receive tacrolimus 0.1 mg/kg/day. CYP3A5\*3/\*3 patients will received tacrolimus 0.08 mg/kg/day. Tacrolimus target level for this phase will be 5-8 ng/ml.